Hologic, Inc. (NASDAQ:HOLX) Stake Boosted by Bridges Investment Management Inc.

Bridges Investment Management Inc. increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 111.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,227 shares of the medical equipment provider's stock after buying an additional 12,234 shares during the quarter. Bridges Investment Management Inc.'s holdings in Hologic were worth $1,435,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. EverSource Wealth Advisors LLC increased its stake in Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares during the period. Smartleaf Asset Management LLC raised its stake in Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after buying an additional 159 shares during the last quarter. Raiffeisen Bank International AG purchased a new position in Hologic during the fourth quarter valued at $49,000. West Financial Advisors LLC purchased a new position in Hologic during the first quarter valued at $50,000. Finally, Covestor Ltd raised its stake in Hologic by 49.3% during the fourth quarter. Covestor Ltd now owns 1,033 shares of the medical equipment provider's stock valued at $75,000 after buying an additional 341 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Morgan Stanley cut their target price on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. Stephens reduced their price objective on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research note on Tuesday, May 13th. Raymond James Financial reiterated an "outperform" rating and set a $71.00 price objective (down previously from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Wall Street Zen cut shares of Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Finally, Citigroup upgraded shares of Hologic from a "neutral" rating to a "buy" rating and increased their target price for the company from $60.00 to $80.00 in a research report on Wednesday. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Hologic presently has a consensus rating of "Hold" and an average price target of $78.75.

Insider Transactions at Hologic

In other news, Director Martin D. Madaus bought 5,445 shares of the stock in a transaction that occurred on Wednesday, May 7th. The shares were purchased at an average cost of $55.24 per share, with a total value of $300,781.80. Following the completion of the acquisition, the director directly owned 5,445 shares in the company, valued at approximately $300,781.80. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.88% of the stock is currently owned by insiders.

Hologic Trading Down 1.3%

HOLX traded down $0.87 on Friday, reaching $65.98. 888,587 shares of the company's stock were exchanged, compared to its average volume of 2,381,453. The company's 50 day moving average is $61.32 and its 200-day moving average is $63.59. The company has a market cap of $14.70 billion, a price-to-earnings ratio of 27.83, a PEG ratio of 2.41 and a beta of 0.55. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.67. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The company had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1 billion. During the same period in the prior year, the business posted $1.03 EPS. The business's revenue was down 1.2% on a year-over-year basis. Equities analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.